Q-omics provides the consensus-scored ACKR2 profile across patient tissues and cancer cell-line models. ACKR2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ACKR2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, ACKR2 RNA expression shows 17,604 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, COAD, and THYM as cancer lineages where ACKR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACKR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACKR2 survival associations across molecular data types. ACKR2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACKR2 RNA expression–survival associations across cancer types. High ACKR2 expression shows unfavorable associations in THCA, but favorable associations in UVM, LIHC, ESCA, UCS and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ACKR2 RNA expression.
This table summarizes ACKR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ACKR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACKR2 shows lower tumor expression in COAD, KIRC, THCA, HNSC and KIRP and higher tumor expression in BLCA. The COAD box plot shows higher ACKR2 RNA expression in normal versus tumor tissue (log2 FC = −1.394, t-test p < 0.001).
This table shows molecular features associated with ACKR2 in patient tissues and cancer cell lines. In patient samples, ACKR2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ACKR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BONE and OVARY.
